$55.18 Million in Sales Expected for Transcat, Inc. (NASDAQ:TRNS) This Quarter

Equities research analysts predict that Transcat, Inc. (NASDAQ:TRNSGet Rating) will report $55.18 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Transcat’s earnings, with the highest sales estimate coming in at $55.46 million and the lowest estimate coming in at $54.90 million. Transcat reported sales of $48.76 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 13.2%. The business is expected to issue its next earnings results after the market closes on Monday, January 1st.

According to Zacks, analysts expect that Transcat will report full year sales of $204.22 million for the current year, with estimates ranging from $203.90 million to $204.54 million. For the next fiscal year, analysts forecast that the business will post sales of $219.56 million, with estimates ranging from $217.81 million to $221.30 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Transcat.

A number of equities analysts have recently issued reports on TRNS shares. StockNews.com started coverage on shares of Transcat in a research report on Thursday, March 31st. They set a “hold” rating on the stock. Zacks Investment Research lowered shares of Transcat from a “hold” rating to a “strong sell” rating in a research report on Tuesday, April 5th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $81.00.

Shares of TRNS traded down $1.08 during mid-day trading on Friday, reaching $69.28. 61,476 shares of the company’s stock were exchanged, compared to its average volume of 27,372. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.34 and a quick ratio of 1.77. The stock has a market capitalization of $520.99 million, a PE ratio of 45.58 and a beta of 0.82. The business’s fifty day simple moving average is $76.23 and its 200-day simple moving average is $83.18. Transcat has a 52-week low of $46.86 and a 52-week high of $101.05.

In other news, Director Gary J. Haseley purchased 1,305 shares of the business’s stock in a transaction dated Tuesday, February 15th. The stock was acquired at an average price of $76.62 per share, with a total value of $99,989.10. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Lee D. Rudow sold 5,210 shares of Transcat stock in a transaction on Saturday, March 26th. The stock was sold at an average price of $74.21, for a total value of $386,634.10. The disclosure for this sale can be found here. 6.60% of the stock is currently owned by company insiders.

Hedge funds have recently made changes to their positions in the stock. US Bancorp DE grew its holdings in Transcat by 137.9% in the 1st quarter. US Bancorp DE now owns 345 shares of the scientific and technical instruments company’s stock valued at $28,000 after buying an additional 200 shares during the period. Marshall Wace North America L.P. grew its holdings in Transcat by 157.5% in the 1st quarter. Marshall Wace North America L.P. now owns 1,545 shares of the scientific and technical instruments company’s stock valued at $36,000 after buying an additional 945 shares during the period. Royal Bank of Canada grew its holdings in Transcat by 30.4% in the 3rd quarter. Royal Bank of Canada now owns 631 shares of the scientific and technical instruments company’s stock valued at $40,000 after buying an additional 147 shares during the period. Covestor Ltd purchased a new stake in Transcat in the 4th quarter valued at about $44,000. Finally, Denali Advisors LLC purchased a new stake in Transcat in the 4th quarter valued at about $46,000. 75.11% of the stock is owned by hedge funds and other institutional investors.

About Transcat (Get Rating)

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates in two segments, Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.

Recommended Stories

Get a free copy of the Zacks research report on Transcat (TRNS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Transcat (NASDAQ:TRNS)

Receive News & Ratings for Transcat Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transcat and related companies with MarketBeat.com's FREE daily email newsletter.